SRR1310008
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.381
- PANCREAS_BETA_CELLS+0.292
- HEDGEHOG_SIGNALING+0.266
- SPERMATOGENESIS+0.256
- OXIDATIVE_PHOSPHORYLATION+0.220
- MYOGENESIS+0.155
- UV_RESPONSE_DN+0.103
- ESTROGEN_RESPONSE_EARLY+0.089
- FATTY_ACID_METABOLISM+0.060
- ESTROGEN_RESPONSE_LATE+0.057
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- IL6_JAK_STAT3_SIGNALING-0.537
- INTERFERON_GAMMA_RESPONSE-0.532
- E2F_TARGETS-0.477
- MYC_TARGETS_V1-0.467
- INFLAMMATORY_RESPONSE-0.436
- ALLOGRAFT_REJECTION-0.430
- G2M_CHECKPOINT-0.414
- TGF_BETA_SIGNALING-0.389
- APOPTOSIS-0.378
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1353176 | GTEX | — | 0.978 |
| 2 | SRR1401424 | GTEX | — | 0.975 |
| 3 | SRR1466993 | GTEX | — | 0.973 |
| 4 | SRR1324371 | GTEX | — | 0.972 |
| 5 | SRR1343841 | GTEX | — | 0.972 |
| 6 | SRR1459441 | GTEX | — | 0.970 |
| 7 | SRR1416434 | GTEX | — | 0.970 |
| 8 | SRR1331335 | GTEX | — | 0.969 |
| 9 | SRR1474951 | GTEX | — | 0.969 |
| 10 | SRR1486097 | GTEX | — | 0.968 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.381 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.292 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.266 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.256 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.155 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.103 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.089 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.057 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.054 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.035 | Temsirolimus | — uncovered |